TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

A Vanderstichele; N Concin; P Busschaert; I Braicu; P Combe; I Ray-Coquard; F Joly; P Harter; P Wimberger; F Selle; A Ignatov; B Schmalfeldt; E Van Nieuwenhuysen; S Darb-Esfahani; A Zeimet; S Mahner; E Pujade-Lauraine; C Marth; R Berger; J Sehouli; U Moll; R Zeillinger; D Lambrechts; I Vergote

doi:10.1136/ijgc-2019-ESGO.11

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Best Oral Communications/Late-Breaking Abstracts 3 – Ovarian Cancer

TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password